Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.32 -3.22%

-$0.14 today

Market cap
$192.16M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.42M

Average 0.38M

PRLD Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin at -309.5%

Operating margin was -309.5% in Q1 FY2026. On a trailing-twelve-month basis it was -503.2%, up 1496.5 pp year over year.

What to watch

Whether operating margin reaches the consensus estimate from 2 analysts of -207.8% for the fiscal year ending Dec 2026, up from -861.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-309.5%-2.0 pp QoQ
Last fiscal yearDec 2025
-861.3%+1134.6 pp YoY
LTMMar 2026
-503.2%+1496.5 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+1134.6 pp+653.6 pp-481.0 pp
3 years—+841.0 pp—
5 years+909.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-861.3%
Year-over-year change
+1134.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How PRLD compares with its peers on the latest reported figures

  • PRLD's LTM Mar 2026 operating margin of -503.2% is the 4th highest of the 9 companies compared; the peer median is -897.6%.
  • Its year-over-year change of +1496.5 pp is the 2nd highest of 7, against a peer median of +99.7 pp.
PRLD Competitors Peer median
Operating Margin for PRLD and competitors
Company Period LTM level YoY 3-year change
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-87.2% +71.2 pp+13.1 pp
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-168.0% +2215.9 pp+769.6 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-286.2% +128.2 pp+343.6 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-503.2% +1496.5 pp—
PYXSPyxis Oncology, Inc.LTM Mar 2026-619.6% ——
CRBUCaribou Biosciences, Inc.LTM Mar 2026-1175.7% +473.1 pp-452.3 pp
IVAInventiva S.A.FY2025-2921.0% -1860.3 pp-2452.0 pp
TNYATenaya Therapeutics, Inc.LTM Mar 2026-38159.1% ——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-134164.4% -122732.2 pp-123394.3 pp
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
IMRXImmuneering CorporationFY2025— ——
Peer median (excluding PRLD) -897.6%+99.7 pp-219.6 pp

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0007M12.14M
Cost of Revenue00001.71M
Gross Profit0007M10.43M
Gross Margin———100.0%85.9%
Research & Development86.78M92.89M103.39M118M94.3M
Selling, General & Admin26.96M30.65M28.88M28.72M22.41M
Operating Expenses113.74M123.54M132.28M146.71M115M
Depreciation & Amortization915K1.32M1.17M1.77M1.71M
EBITDA(110.78M)(114.11M)(120.66M)(125.4M)(97.79M)
EBITDA Margin———-1791.4%-805.5%
Operating Income(113.74M)(123.54M)(132.28M)(139.71M)(104.57M)
Operating Margin———-1995.9%-861.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses2.04M8.1M10.44M12.54M5.07M
Income Before Tax(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Pre-Tax Margin———-1816.8%-819.6%
Income Tax Expense00000
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Net Margin———-1816.8%-819.6%
EPS (Basic)(2.33)(2.27)(2.02)(1.68)(1.29)
EPS (Diluted)(2.33)(2.27)(2.02)(1.68)(1.29)
Weighted Avg Shares47.6M47.37M60.36M75.81M76.96M
Weighted Avg Shares (Diluted)47.6M47.37M60.36M75.81M76.96M

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.